Tag Archives: Carcinoid Support Group

Mitch Berger – In Memory

Posted on November 17, 2019 by cacsnets

Mitchell Andrew Berger November 30, 1955-November 10, 2019 Tributes about Mitch have been coming in from many sources – old friends, relatives, fellow travelers down the complicated Neuroendocrine Tumors’ (NETs) pathways.  He was a guide and a listener.  Everyone recognizes … Continue reading →

Posted in Tributes | Tagged , , , , | 1 Comment

Patient & Caregiver Seminar – Norfolk, VA Feb 16th

Posted on February 6, 2018 by cacsnets

Eastern Virginia Medical School, Norfolk, VA will Host AN UPDATE ON THE MANAGEMENT OF NEUROENDOCRINE TUMORS for Patients and their Caregivers Friday, February 16, 2018 1:30 pm—4:00 pm      Lester Hall, EVMS Campus (across from CHKD)          … Continue reading →

Posted in Events, Past Events, Uncategorized | Tagged , , , , , , | Leave a comment

NANETS Attendees Brief CACS Members

Posted on January 30, 2018 by cacsnets

CACS sponsored 5 area physicians to attend the North American Neuroendocrine Tumor Society (NANETS) meeting in November, 2017.  Those physicians have been returning to CACS and sharing information information. Dr. Amit Tirosh, NIH Research and Endocrinologist visited on Jan 13, … Continue reading →

Posted in News & Resources, Past Events, Uncategorized | Tagged , , , , , , | Leave a comment

Third Theranostics World Congress on Ga-68 and PRRT Draws International Audience

Posted on April 11, 2015 by cacsnets

An international audience came together for the Third Theranostics World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, March 12–14 on the Johns Hopkins Medical Institutes campus in Baltimore, Md. Accepted abstracts will be published as a supplement to a … Continue reading →

Posted in News & Resources | Tagged , , , , , , , , , , , , | Leave a comment

News – FDA Approves Lanreotide

Posted on December 17, 2014 by cacsnets

On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline® Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free … Continue reading →

Posted in News & Resources | Tagged , , , , , , , , , | Leave a comment